Eckert & Ziegler and GlyTherix Expand Collaboration with Actinium-225 Supply Agreement

Eckert & Ziegler and GlyTherix Ltd have announced an extension of their collaboration to include a global supply agreement for Actinium-225 (Ac-225). This development supports GlyTherix’s research on innovative radiotherapeutics targeting solid tumors. The agreement follows the start of Ac-225 production, in conjunction with the Nuclear Physics Institute of the Czech Academy of Sciences.

The collaboration aims to develop antibody radiopharmaceuticals that target Glypican-1, a protein linked to aggressive cancers, delivering localized radiation to tumors. GlyTherix plans to initiate trials in early 2025 in Australia and the US by 2026, leveraging the Ac-225 supply to advance their clinical program.

Both companies express optimism about the potential impact on cancer therapy accessibility worldwide, emphasizing the importance of a reliable supply chain for the alpha emitter.